Billionaire hedge fund manager John Paulson has more than tripled the size of his stake in Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), which could suggest the biotech giant has a lot more upside ahead of it.
Valeant has become a favourite among hedge funds. Since 2010 shares have climbed more than 15-fold, making early investors rich in the process. However, Paulson’s position indicates the company still has a long-growth runway.
According to SEC filings published last week, the money manager increased his stake in Valeant nearly fourfold during the first quarter. Today his hedge fund Paulson & Co. owns a US$400 million position in the company as of March 31, up from under US$100 million at the start of the year.
Is Valeant Pharmaceuticals the next Berkshire Hathaway?
While Paulson’s move is a big vote of confidence in Valeant, he’s just one of many big money managers backing the company.
At the annual Sohn Investment Conference earlier this month, billionaire investor Bill Ackman called Valeant “a very early stage Berkshire Hathaway.” In his view the company is much more than a traditional pharmaceutical firm. Instead, Ackman describes Valeant as a platform to carry out investment activities in much the same way Berkshire is a platform for Warren Buffett’s business dealings.
To some extent, Ackman’s view is correct. Management’s strategy has been to buy up small and mid-size drug makers, then push their finished products through Valeant’s deep distribution network. As Fortune noted, the company has made more than 100 acquisitions since 2008.
Most of Valeant’s purchases have been pharmaceutical-based. However, the company did agree to acquire Bausch & Lomb last year in order to break into the ophthalmic and eye vision business. This has added a substantial degree of diversity to Valeant’s product portfolio.
Ackman estimates that Valeant should be able to complete between US$7 billion and US$20 billion worth of acquisitions on an annual basis. Based on that assumption, he believes the stock should be worth more than US$330 a share—50% higher from where it trades today.
If you don’t buy Valeant now, you’ll kick yourself later
However, John Paulson and Bill Ackman aren’t the only ones who see an opportunity.
According to SEC filings, famed value investor Jeffrey Ubben now owns a US$2.7 billion (yes, that’s billion with a b) stake in Valeant. A number of other hedge fund managers—including D.E. Shaw, Jim Simons, and Israel Englander—have been building positions in the company as well.
What could have these smart money managers so excited? I’d say it could only mean one thing—they see an epic rally ahead.
Motley Fool Canada's market-beating team has just released a brand-new FREE report revealing 5 "dirt cheap" stocks that you can buy today for under $49 a share.
Our team thinks these 5 stocks are critically undervalued, but more importantly, could potentially make Canadian investors who act quickly a fortune.
Don't miss out! Simply click the link below to grab your free copy and discover all 5 of these stocks now.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.
Fool contributor Robert Baillieul has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Berkshire Hathaway and Valeant Pharmaceuticals.